Tolvaptan

Active substance Tolvaptan
Holder Otsuka Pharmaceutical Development and Commercialization, Inc
Status Running
Indication Treatment of Children and Adolescent Patients until they reach 18 years of age with Autosomal Dominant Polycystic Kidney Disease Following Successful Participation and Completion in the 156-12-298 Clinical Trial
Public documents Approbation
  Information for the patient
  Informed consent
Last update 18/05/2021

 

Last updated on 04/06/2021